[go: up one dir, main page]

AR083797A1 - Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos - Google Patents

Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos

Info

Publication number
AR083797A1
AR083797A1 ARP110104165A ARP110104165A AR083797A1 AR 083797 A1 AR083797 A1 AR 083797A1 AR P110104165 A ARP110104165 A AR P110104165A AR P110104165 A ARP110104165 A AR P110104165A AR 083797 A1 AR083797 A1 AR 083797A1
Authority
AR
Argentina
Prior art keywords
piperazin
amino
cyclopentil
carboxilico
pirimidin
Prior art date
Application number
ARP110104165A
Other languages
English (en)
Original Assignee
Novartis Ag
Astex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45094234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR083797(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Astex Therapeutics Ltd filed Critical Novartis Ag
Publication of AR083797A1 publication Critical patent/AR083797A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Reivindicación 1: La sal de succinato de dimetil-amida del ácido 7-cicIopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7H-pirrolo-[2,3-d]-pirimidin-6-carboxílico.
ARP110104165A 2010-11-10 2011-11-08 Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos AR083797A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41206410P 2010-11-10 2010-11-10

Publications (1)

Publication Number Publication Date
AR083797A1 true AR083797A1 (es) 2013-03-20

Family

ID=45094234

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP110104165A AR083797A1 (es) 2010-11-10 2011-11-08 Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
ARP200100071A AR117799A2 (es) 2010-11-10 2020-01-10 Sal(es) de dimetil-amida del ácido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]-pirimidin-6-carboxílico y procesos para su elaboración

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP200100071A AR117799A2 (es) 2010-11-10 2020-01-10 Sal(es) de dimetil-amida del ácido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]-pirimidin-6-carboxílico y procesos para su elaboración

Country Status (25)

Country Link
US (4) US20120115878A1 (es)
EP (2) EP3753933A1 (es)
JP (4) JP2013542257A (es)
KR (4) KR20180112079A (es)
CN (4) CN105384741B (es)
AR (2) AR083797A1 (es)
AU (4) AU2011326620A1 (es)
BR (2) BR122021022703B1 (es)
CA (1) CA2815839C (es)
CL (1) CL2013001282A1 (es)
CO (1) CO6781544A2 (es)
EC (1) ECSP13012619A (es)
ES (1) ES2803432T3 (es)
GT (1) GT201300123A (es)
IL (1) IL225580B (es)
JO (1) JO3670B1 (es)
MA (1) MA34653B1 (es)
MX (1) MX370852B (es)
MY (1) MY164274A (es)
PE (1) PE20140065A1 (es)
PH (1) PH12013500872A1 (es)
RU (1) RU2631243C2 (es)
SG (1) SG189229A1 (es)
TW (1) TWI549953B (es)
WO (1) WO2012064805A1 (es)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
AR083797A1 (es) * 2010-11-10 2013-03-20 Novartis Ag Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
AU2012279117A1 (en) 2011-07-01 2014-01-09 Novartis Ag Combination therapy comprising a CDK4/6 inhibitor and a PI3K inhibitor for use in the treatment of cancer
WO2014097125A1 (en) * 2012-12-20 2014-06-26 Novartis Ag Pharmaceutical combination comprising binimetinib
AU2015266492B2 (en) * 2014-05-28 2017-11-02 Fochon Pharmaceuticals, Ltd. Certain protein kinase inhibitors
CN105294737B (zh) * 2014-07-26 2019-02-12 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途
SI3218005T1 (sl) 2014-11-12 2023-06-30 Seagen Inc. Z glikanom delujoče spojine, in postopki uporabe
US10138250B2 (en) 2014-12-12 2018-11-27 Crystal Pharmatech Co., Ltd. Salt of pyrrolo[2,3-D]pyrimidine compound and novel polymorph of salt
CN105111215B (zh) * 2014-12-12 2019-06-18 苏州晶云药物科技股份有限公司 一种周期蛋白依赖性激酶抑制剂的晶型及其制备方法
EP3231805B1 (en) * 2014-12-12 2020-03-04 Crystal Pharmatech Co. Ltd. Salt of pyrrolo[2,3-d]pyrimidine compound and novel polymorph of salt
CN107787226A (zh) * 2015-03-25 2018-03-09 诺华股份有限公司 药物组合
WO2016155670A1 (zh) * 2015-04-01 2016-10-06 苏州晶云药物科技有限公司 一种cdk抑制剂和mek抑制剂的共晶及其制备方法
FI3283058T3 (fi) 2015-04-16 2023-03-01 Novartis Ag Ribosiklibitabletti
CN105037236B (zh) 2015-06-04 2017-07-28 苏州明锐医药科技有限公司 瑞博西尼中间体及其制备方法
US20180243304A1 (en) * 2015-08-28 2018-08-30 Novartis Ag Pharmaceutical combinations comprising (a) the cyclin dependent kinase 4/6 (cdk4/6) inhibitor lee011 (=ribociclib), and (b) the epidermal growth factor receptor (egfr) inhibitor erlotinib, for the treatment or prevention of cancer
EP3156406A1 (en) 2015-10-14 2017-04-19 ratiopharm GmbH Crystalline forms of ribociclib free base
CA3002097A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
CN106749259B (zh) * 2015-11-19 2019-02-01 华东师范大学 一种环戊基嘧啶并吡咯类化合物的合成方法
CN107266451B (zh) * 2016-04-07 2021-12-31 上海医药工业研究院 瑞布昔利布中间体的制备方法
WO2017193872A1 (en) 2016-05-07 2017-11-16 Shanghai Fochon Pharmaceutical Co., Ltd. Certain protein kinase inhibitors
RU2769251C2 (ru) 2016-08-23 2022-03-29 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Комбинированная терапия для лечения гепатоцеллюлярной карциномы
WO2018051280A1 (en) * 2016-09-15 2018-03-22 Dr. Reddy’S Laboratories Limited Process for preparation of ribociclib, its acid addition salts
KR102341660B1 (ko) 2016-09-19 2021-12-23 노파르티스 아게 Raf 억제제 및 erk 억제제를 포함하는 치료적 조합
EP3541847A4 (en) 2016-11-17 2020-07-08 Seattle Genetics, Inc. COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
CN108314686A (zh) * 2017-01-18 2018-07-24 西南民族大学 一种新颖的Ribociclib制备方法
EP3589319A4 (en) 2017-03-03 2021-07-14 Seagen Inc. COMPOUNDS INTERACTING WITH GLYCAN AND METHODS OF USE
CN108586356B (zh) * 2017-03-16 2021-02-19 杭州科巢生物科技有限公司 瑞博西尼新中间体及其制备瑞博西尼的合成方法
BR112019019261A2 (pt) 2017-03-16 2020-06-16 Eisai R & D Management Co., Ltd. Terapias de combinação para o tratamento de câncer de mama
CN108623599A (zh) * 2017-03-17 2018-10-09 西南民族大学 一种快速合成Ribociclib方法
CN110494166B (zh) 2017-05-02 2022-11-08 诺华股份有限公司 组合疗法
CN106928236B (zh) * 2017-05-06 2019-05-31 山东君瑞医药科技有限公司 一种瑞博西尼的合成工艺
CN109206373B (zh) * 2017-07-07 2022-02-15 上海医药工业研究院 一种帕博昔布中间体5-溴-2-氯-4-环戊基氨基嘧啶的制备工艺
CN111094290B (zh) * 2017-07-27 2022-06-17 苏州晶云药物科技股份有限公司 瑞博西尼的单琥珀酸盐晶型及其制备方法和用途
EP4327880A3 (en) 2017-08-25 2024-05-22 Assia Chemical Industries Ltd. Solid state form of ribociclib succinate
EP3676404B1 (en) 2017-08-31 2025-09-03 Novartis AG Methods of selecting a treatment for breast cancer patients
US11286259B2 (en) 2017-09-29 2022-03-29 Hangzhou Solipharma Co., Ltd. Co-crystals of ribociclib and co-crystals of ribociclib monosuccinate, preparation method therefor, compositions thereof, and uses thereof
JP7100125B2 (ja) * 2017-10-27 2022-07-12 フレゼニウス・カビ・オンコロジー・リミテッド リボシクリブおよびその塩の改善された調製のためのプロセス
WO2019111160A1 (en) * 2017-12-04 2019-06-13 Sun Pharmaceutical Industries Limited Crystalline forms of ribociclib succinate
WO2019123364A1 (en) * 2017-12-22 2019-06-27 Shilpa Medicare Limited Novel polymorphs of ribociclib mono succinate
WO2019130068A1 (en) * 2017-12-29 2019-07-04 Dr. Reddy’S Laboratories Limited Crystalline forms of ribociclib succinate
CN107936029B (zh) * 2018-01-08 2020-06-30 南京奇可药业有限公司 一种合成瑞博西尼的方法
CN110016024B (zh) * 2018-01-09 2021-09-03 南京药石科技股份有限公司 一种合成cdk4/6双重抑制剂的关键中间体及其制备方法和应用
US11414421B2 (en) 2018-01-20 2022-08-16 Natco Pharma Ltd Process for the preparation of ribociclib succinate and its novel crystalline forms thereof
WO2019150181A1 (en) * 2018-02-05 2019-08-08 Biophore India Pharmaceuticals Pvt Ltd Improved process for the preparation of 7-cyclopentyl-n, n-dimethyl-2-(5-(piperazin-1-yl) pyridin-2-ylaminuteso)-7h-pyrrolo[2,3-d] pyrimidine-6-carboxamide succinate (ribociclib succinate) and its crystalline forms thereof
WO2019166987A1 (en) * 2018-02-28 2019-09-06 Sun Pharmaceutical Industries Limited A process for the preparation of ribociclib and its intermediates
WO2019167068A1 (en) 2018-03-01 2019-09-06 Cipla Limited Novel polymorphs of ribociclib succinate
CA3043066A1 (en) 2018-05-14 2019-11-14 Apotex Inc. Processes for the preparation of ribociclib and intermediates thereof
TWI675662B (zh) 2018-05-17 2019-11-01 中化合成生技股份有限公司 瑞博西尼琥珀酸鹽（Ｒｉｂｏｃｉｃｌｉｂ ｓｕｃｃｉｎａｔｅ ｓａｌｔ）晶型Ｂ、Ｃ及Ｄ與其衍生物，以及其等之製造方法與藥物組合物
CA3048036A1 (en) 2018-07-02 2020-01-02 Apotex Inc Novel crystalline form of ribociclib succinate
CN110156793B (zh) * 2018-07-13 2022-01-14 安礼特（上海）医药科技有限公司 瑞博西尼单琥珀酸盐新晶型及制备方法
WO2020084389A1 (en) 2018-10-23 2020-04-30 Lupin Limited Ribociclib intermediate and process for preparation thereof
CN114269345B (zh) * 2018-10-26 2025-06-27 科乐斯疗法公司 Alk2抑制剂的晶体形式
CN111100128B (zh) * 2018-10-26 2022-09-06 广安凯特制药有限公司 一种瑞博西尼中间产品的合成方法及其中间体化合物
CN113195000A (zh) 2018-12-21 2021-07-30 第一三共株式会社 抗体-药物缀合物和激酶抑制剂的组合
CN109400612A (zh) * 2018-12-24 2019-03-01 重庆三圣实业股份有限公司 一种瑞博西尼的制备方法及其产品和用途
KR20210119444A (ko) * 2019-01-23 2021-10-05 노파르티스 아게 7-사이클로펜틸-2-(5-피페라진-1-일-피리딘-2-일아미노)-7h-피롤로[2,3-d]피리미딘-6-카복실산 디메틸아미드의 석신산염의 신규한 결정질 형태
WO2020225827A1 (en) * 2019-05-08 2020-11-12 Mylan Laboratories Limited Novel polymorphs of ribociclib succinate
BR112021022335A2 (pt) 2019-05-13 2021-12-28 Novartis Ag Formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinopiridin-4-il)-4-metilfenil)-2 (trifluorome-til)isonicotinamida como inibidores raf para o tratamento de câncer
CN112010857B (zh) * 2019-05-30 2021-11-05 常州制药厂有限公司 一种瑞博西尼单丁二酸盐的晶型
KR20220054347A (ko) 2019-08-26 2022-05-02 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 유도체로 유방암을 치료하는 방법
WO2021038590A1 (en) 2019-08-30 2021-03-04 Mylan Laboratories Limited Novel polymorph of ribociclib succinate
US20240000789A1 (en) 2020-05-12 2024-01-04 Novartis Ag Therapeutic combinations comprising a craf inhibitor
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
EP4313987A2 (en) 2021-04-01 2024-02-07 KRKA, d.d., Novo mesto Process for the preparation of ribociclib and pharmaceutically acceptable salts thereof
EP4370126A4 (en) 2021-07-16 2025-05-28 Dana-Farber Cancer Institute, Inc. Small molecule cyclin dependent kinase 4/6 (cdk4/6) and ikzf2 (helios) degraders and methods of use thereof
CN113636973B (zh) * 2021-09-07 2023-04-07 山东铂源药业股份有限公司 一种4-(6-氨基吡啶-3-基)哌嗪-1-羧酸叔丁酯的工业化制备方法
KR20240118134A (ko) 2021-12-10 2024-08-02 일라이 릴리 앤드 캄파니 Cdk4 및 6 억제제로 이전에 치료된 환자에서의 호르몬 수용체-양성, 인간 표피 성장 인자 수용체 2-음성 진행성 또는 전이성 유방암의 치료를 위한 풀베스트란트와 조합된 cdk4 및 6 억제제
WO2023114264A1 (en) 2021-12-15 2023-06-22 Eli Lilly And Company Combination for treatment of high-risk metastatic hormone-sensitive prostate cancer
TWI848533B (zh) 2022-01-25 2024-07-11 瑞士商諾華公司 瑞博西尼藥物組成物
EP4580631A1 (en) 2022-08-31 2025-07-09 Arvinas Operations, Inc. Dosage regimens of estrogen receptor degraders
JP2024067010A (ja) 2022-11-02 2024-05-16 ペトラ・ファーマ・コーポレイション 疾患の治療用のホスホイノシチド３－キナーゼ（ｐｉ３ｋ）のアロステリッククロメノン阻害剤
WO2024115680A1 (en) 2022-12-01 2024-06-06 Krka, D.D., Novo Mesto Ribociclib salts and formulations thereof
CN117069663B (zh) * 2023-08-31 2023-12-26 四川维亚本苑生物科技有限公司 一种瑞博西尼中间体v的合成方法及瑞博西尼的合成方法
WO2025051337A1 (en) 2023-09-06 2025-03-13 Afyx Development A/S Compositions and methods for treating and preventing oral cancer
WO2025219830A1 (en) * 2024-04-15 2025-10-23 Novartis Ag Pharmaceutical compositions of ribociclib
CN120118041B (zh) * 2025-05-12 2025-08-01 瑞博(苏州)制药有限公司 一种瑞博西尼中间体的制备方法及用途
CN120329307A (zh) * 2025-06-18 2025-07-18 瑞博(苏州)制药有限公司 Lee011中间体的新晶型及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI992711A1 (it) 1999-12-27 2001-06-27 Novartis Ag Composti organici
MXPA04005861A (es) * 2001-12-20 2004-10-29 Osi Pharm Inc Compuestos antagonistas selectivos de pirrolopirimidina a2b, su sintesis y uso.
WO2005023761A2 (en) 2003-09-11 2005-03-17 Kemia, Inc. Cytokine inhibitors
EP1713806B1 (en) * 2004-02-14 2013-05-08 Irm Llc Compounds and compositions as protein kinase inhibitors
US20080167309A1 (en) * 2004-07-22 2008-07-10 Astex Therapeutics, Ltd. Pharmaceutical Compounds
WO2006091737A1 (en) * 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
EP1910218A1 (en) 2005-07-22 2008-04-16 Qualcomm Mems Technologies, Inc. Mems devices having support structures and methods of fabricating the same
BRPI0620151A2 (pt) 2005-12-22 2010-06-29 Wyeth Corp composto; composição farmacêutica; método de tratar ou inibir o crescimento de células tumorais cancerosas em um mamìfero que deste necessita; método; e processo
TWI398252B (zh) * 2006-05-26 2013-06-11 Novartis Ag 吡咯并嘧啶化合物及其用途
CN102186856B (zh) * 2008-08-22 2014-09-24 诺华股份有限公司 作为cdk抑制剂的吡咯并嘧啶化合物
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR083797A1 (es) 2010-11-10 2013-03-20 Novartis Ag Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos

Also Published As

Publication number Publication date
RU2013126112A (ru) 2014-12-20
PH12013500872A1 (en) 2016-04-01
CA2815839C (en) 2019-08-06
US20150099760A1 (en) 2015-04-09
IL225580B (en) 2018-05-31
SG189229A1 (en) 2013-06-28
TWI549953B (zh) 2016-09-21
US9868739B2 (en) 2018-01-16
RU2631243C2 (ru) 2017-09-20
AU2018274883A1 (en) 2018-12-20
CA2815839A1 (en) 2012-05-18
JO3670B1 (ar) 2020-08-27
AU2016203534B2 (en) 2017-09-14
WO2012064805A1 (en) 2012-05-18
CN105384741B (zh) 2019-11-19
AU2018274883B2 (en) 2020-07-09
AR117799A2 (es) 2021-08-25
IL225580A0 (en) 2013-06-27
BR112013010167A2 (pt) 2016-09-13
ES2803432T3 (es) 2021-01-26
GT201300123A (es) 2014-06-09
KR20190099090A (ko) 2019-08-23
MA34653B1 (fr) 2013-11-02
US9193732B2 (en) 2015-11-24
AU2016203534A1 (en) 2016-06-16
CN113956257A (zh) 2022-01-21
AU2011326620A1 (en) 2013-05-02
US20130217698A1 (en) 2013-08-22
MY164274A (en) 2017-11-30
KR20130132433A (ko) 2013-12-04
TW201305169A (zh) 2013-02-01
MX2013005292A (es) 2013-08-01
MX370852B (es) 2020-01-08
EP2638030A1 (en) 2013-09-18
BR112013010167B1 (pt) 2022-02-15
ECSP13012619A (es) 2013-07-31
JP2013542257A (ja) 2013-11-21
CN105384741A (zh) 2016-03-09
CL2013001282A1 (es) 2013-09-27
PE20140065A1 (es) 2014-01-27
KR20200136493A (ko) 2020-12-07
CN103201275A (zh) 2013-07-10
EP3753933A1 (en) 2020-12-23
EP2638030B1 (en) 2020-04-15
JP2017057203A (ja) 2017-03-23
JP6534375B2 (ja) 2019-06-26
KR20180112079A (ko) 2018-10-11
JP2017039757A (ja) 2017-02-23
US20120115878A1 (en) 2012-05-10
CO6781544A2 (es) 2013-10-31
AU2017221805A1 (en) 2017-09-21
US20160039832A1 (en) 2016-02-11
BR122021022703B1 (pt) 2022-07-19
CN105399743A (zh) 2016-03-16
JP2019038809A (ja) 2019-03-14

Similar Documents

Publication Publication Date Title
AR083797A1 (es) Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
LT3486245T (lt) 2-amino-n-(piperidin-1-il-piridin-3-il)pirazolo[1,5alfa]pirimidin-3-karboksamidas, kaip atr kinazės inhibitorius
CR20140576A (es) Sintesis de compuestos heterociclicos
MX363347B (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
MX354021B (es) Derivados de 5-fluor-4-imino-3- (sustituido) -3,4-dihidropirimidin -2 (1h) ona.
EA201390199A1 (ru) 2-замещенные-8-алкил-7-оксо-7,8-дигидропиридо[2,3-d]пиримидин-6-карбонитрилы и их применение
SI2776442T1 (sl) Derivati (1,2,3)triazolo(4,5-d)pirimidina kot agonisti kanabinoidnega receptorja 2
UY34467A (es) Procedimiento para la preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
BR112012029647A2 (pt) novos derivados de pirimidinas
ECSP13012519A (es) Compuestos sustituidos de benzamida
CL2015000408A1 (es) Compuestos derivados de pirazolo[4,3-d]pirimidina y sus sales; composicion farmaceutica que los comprende, util para el tratamiento de enfermedades alergicas, inflamatorias, infecciosas o cancer.
FR2962731B1 (fr) Procede de preparation de derives d'amino-benzoyl-benzofurane
UY34018A (es) Derivados glucósidos y usos de los mismos
ZA201403441B (en) [1,2,3]triazolo[4,5-d]pyrimidine derivatives as agonists of the cannabinoid
CU24293B1 (es) Procedimiento de preparación de la sal de l-arginina de perindoprilo
ECSP13012914A (es) Síntesis de derivados de 2-carboxamida-cicloamino-urea
UY34023A (es) Derivados de fenil-isoxazol y procedimiento para la preparación de los mismos
UY34223A (es) Formulaciones de (trimetoxifenilamino)pirimidinilo nuevas
UY34552A (es) Forma cristalina delta de la sal de arginina de perindoprilo, su procedimiento de preparación, y las composiciones farmacéuticas que la contienen
CL2012003206A1 (es) Proceso para preparar derivados de n-bifenil-ilmetil-2-[2-(bencilsulfanil)-4-oxo-ciclopenta[d]pirimidin]acetamida; los compuestos intermediarios considerados; y los procesos de preparación de los intermediarios.
IT1405996B1 (it) Procedimento per la preparazione di 2,5-diaminotoluolo
AU2013338098A8 (en) Solid salt form of alpha-6-mPEG6-O-hydroxycodone as opioid agonists and uses thereof
MX2012014304A (es) Carboxamidas de pirazinilo como fungicidas.
CR20150160A (es) Derivados de macrólidos, su preparación y su uso terapéutico
ITMI20130038A1 (it) Procedimento per la preparazione di composti benzoetero[1,3]diazolici disostituiti con gruppi eteroarilici

Legal Events

Date Code Title Description
FG Grant, registration